Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Legrand-Abravanel, F., Colson, P., Leguillou-Guillemette, H., Alric, L., Ravaux, I., Lunel-Fabiani, F., Bouviers-Alias, M., Trimoulet, P., Chaix, M. L., Hezode, C., Foucher, J., Fontaine, H., Roque-Afonso, A. M., Gassin, M., Schvoerer, E., Gaudy, C., Roche, B., Doffoel, M., D'Alteroche, L., Vallet, S., Baazia, Y., Pozzetto, B., Thibault, V., Nousbaum, J. B., Roulot, D., Coppere, H., Poynard, T., Payan, C., & Izopet, J. J Med Virol, 81(12):2029–35, December, 2009. abstract bibtex The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39%) tended to be higher than that of patients infected with subtype 1a (30.6%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3%; P = 0.12) or 4d (51.7%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7-5.0; P \textless 0.01), absence of HIV co-infection (OR: 2.08; 95% CI = 1.2-3.5; P \textless 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95% CI = 1.2-2.6; P \textless 0.01), and the subtype 1b (OR: 1.61; 95% CI = 1.0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d.
@article{legrand-abravanel_influence_2009,
title = {Influence of the {HCV} subtype on the virological response to pegylated interferon and ribavirin therapy},
volume = {81},
issn = {1096-9071 (ELECTRONIC); 0146-6615 (LINKING)},
shorttitle = {Influence of the {HCV} subtype on the virological response to pegylated interferon and ribavirin therapy},
abstract = {The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8\%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39\%) tended to be higher than that of patients infected with subtype 1a (30.6\%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3\%; P = 0.12) or 4d (51.7\%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95\% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95\% CI = 1.7-5.0; P {\textless} 0.01), absence of HIV co-infection (OR: 2.08; 95\% CI = 1.2-3.5; P {\textless} 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95\% CI = 1.2-2.6; P {\textless} 0.01), and the subtype 1b (OR: 1.61; 95\% CI = 1.0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95\% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d.},
number = {12},
journal = {J Med Virol},
author = {Legrand-Abravanel, F. and Colson, P. and Leguillou-Guillemette, H. and Alric, L. and Ravaux, I. and Lunel-Fabiani, F. and Bouviers-Alias, M. and Trimoulet, P. and Chaix, M. L. and Hezode, C. and Foucher, J. and Fontaine, H. and Roque-Afonso, A. M. and Gassin, M. and Schvoerer, E. and Gaudy, C. and Roche, B. and Doffoel, M. and D'Alteroche, L. and Vallet, S. and Baazia, Y. and Pozzetto, B. and Thibault, V. and Nousbaum, J. B. and Roulot, D. and Coppere, H. and Poynard, T. and Payan, C. and Izopet, J.},
month = dec,
year = {2009},
keywords = {Adult Antiviral Agents/ administration \& dosage Drug Therapy, Chronic/drug therapy/virology Humans Interferon-alpha/ administration \& dosage Male Middle Aged Recombinant Proteins Ribavirin/ administration \& dosage Treatment Outcome, Combination Female Genetic Variation Genome, Viral Hepacivirus/drug effects/genetics Hepatitis C},
pages = {2029--35},
}
Downloads: 0
{"_id":"wzza9Z68Y98LHdoH8","bibbaseid":"legrandabravanel-colson-leguillouguillemette-alric-ravaux-lunelfabiani-bouviersalias-trimoulet-etal-influenceofthehcvsubtypeonthevirologicalresponsetopegylatedinterferonandribavirintherapy-2009","author_short":["Legrand-Abravanel, F.","Colson, P.","Leguillou-Guillemette, H.","Alric, L.","Ravaux, I.","Lunel-Fabiani, F.","Bouviers-Alias, M.","Trimoulet, P.","Chaix, M. L.","Hezode, C.","Foucher, J.","Fontaine, H.","Roque-Afonso, A. M.","Gassin, M.","Schvoerer, E.","Gaudy, C.","Roche, B.","Doffoel, M.","D'Alteroche, L.","Vallet, S.","Baazia, Y.","Pozzetto, B.","Thibault, V.","Nousbaum, J. B.","Roulot, D.","Coppere, H.","Poynard, T.","Payan, C.","Izopet, J."],"bibdata":{"bibtype":"article","type":"article","title":"Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy","volume":"81","issn":"1096-9071 (ELECTRONIC); 0146-6615 (LINKING)","shorttitle":"Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy","abstract":"The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39%) tended to be higher than that of patients infected with subtype 1a (30.6%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3%; P = 0.12) or 4d (51.7%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7-5.0; P \\textless 0.01), absence of HIV co-infection (OR: 2.08; 95% CI = 1.2-3.5; P \\textless 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95% CI = 1.2-2.6; P \\textless 0.01), and the subtype 1b (OR: 1.61; 95% CI = 1.0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d.","number":"12","journal":"J Med Virol","author":[{"propositions":[],"lastnames":["Legrand-Abravanel"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Colson"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Leguillou-Guillemette"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Alric"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Ravaux"],"firstnames":["I."],"suffixes":[]},{"propositions":[],"lastnames":["Lunel-Fabiani"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Bouviers-Alias"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Trimoulet"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Chaix"],"firstnames":["M.","L."],"suffixes":[]},{"propositions":[],"lastnames":["Hezode"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Foucher"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Fontaine"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Roque-Afonso"],"firstnames":["A.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Gassin"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Schvoerer"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Gaudy"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Roche"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Doffoel"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["D'Alteroche"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Vallet"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Baazia"],"firstnames":["Y."],"suffixes":[]},{"propositions":[],"lastnames":["Pozzetto"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Thibault"],"firstnames":["V."],"suffixes":[]},{"propositions":[],"lastnames":["Nousbaum"],"firstnames":["J.","B."],"suffixes":[]},{"propositions":[],"lastnames":["Roulot"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Coppere"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Poynard"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Payan"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Izopet"],"firstnames":["J."],"suffixes":[]}],"month":"December","year":"2009","keywords":"Adult Antiviral Agents/ administration & dosage Drug Therapy, Chronic/drug therapy/virology Humans Interferon-alpha/ administration & dosage Male Middle Aged Recombinant Proteins Ribavirin/ administration & dosage Treatment Outcome, Combination Female Genetic Variation Genome, Viral Hepacivirus/drug effects/genetics Hepatitis C","pages":"2029–35","bibtex":"@article{legrand-abravanel_influence_2009,\n\ttitle = {Influence of the {HCV} subtype on the virological response to pegylated interferon and ribavirin therapy},\n\tvolume = {81},\n\tissn = {1096-9071 (ELECTRONIC); 0146-6615 (LINKING)},\n\tshorttitle = {Influence of the {HCV} subtype on the virological response to pegylated interferon and ribavirin therapy},\n\tabstract = {The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8\\%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39\\%) tended to be higher than that of patients infected with subtype 1a (30.6\\%; P = 0.06) and it was similar to those patients infected with subtypes 4a (51.3\\%; P = 0.12) or 4d (51.7\\%; P = 0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95\\% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95\\% CI = 1.7-5.0; P {\\textless} 0.01), absence of HIV co-infection (OR: 2.08; 95\\% CI = 1.2-3.5; P {\\textless} 0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95\\% CI = 1.2-2.6; P {\\textless} 0.01), and the subtype 1b (OR: 1.61; 95\\% CI = 1.0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95\\% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d.},\n\tnumber = {12},\n\tjournal = {J Med Virol},\n\tauthor = {Legrand-Abravanel, F. and Colson, P. and Leguillou-Guillemette, H. and Alric, L. and Ravaux, I. and Lunel-Fabiani, F. and Bouviers-Alias, M. and Trimoulet, P. and Chaix, M. L. and Hezode, C. and Foucher, J. and Fontaine, H. and Roque-Afonso, A. M. and Gassin, M. and Schvoerer, E. and Gaudy, C. and Roche, B. and Doffoel, M. and D'Alteroche, L. and Vallet, S. and Baazia, Y. and Pozzetto, B. and Thibault, V. and Nousbaum, J. B. and Roulot, D. and Coppere, H. and Poynard, T. and Payan, C. and Izopet, J.},\n\tmonth = dec,\n\tyear = {2009},\n\tkeywords = {Adult Antiviral Agents/ administration \\& dosage Drug Therapy, Chronic/drug therapy/virology Humans Interferon-alpha/ administration \\& dosage Male Middle Aged Recombinant Proteins Ribavirin/ administration \\& dosage Treatment Outcome, Combination Female Genetic Variation Genome, Viral Hepacivirus/drug effects/genetics Hepatitis C},\n\tpages = {2029--35},\n}\n\n\n\n","author_short":["Legrand-Abravanel, F.","Colson, P.","Leguillou-Guillemette, H.","Alric, L.","Ravaux, I.","Lunel-Fabiani, F.","Bouviers-Alias, M.","Trimoulet, P.","Chaix, M. L.","Hezode, C.","Foucher, J.","Fontaine, H.","Roque-Afonso, A. M.","Gassin, M.","Schvoerer, E.","Gaudy, C.","Roche, B.","Doffoel, M.","D'Alteroche, L.","Vallet, S.","Baazia, Y.","Pozzetto, B.","Thibault, V.","Nousbaum, J. B.","Roulot, D.","Coppere, H.","Poynard, T.","Payan, C.","Izopet, J."],"key":"legrand-abravanel_influence_2009","id":"legrand-abravanel_influence_2009","bibbaseid":"legrandabravanel-colson-leguillouguillemette-alric-ravaux-lunelfabiani-bouviersalias-trimoulet-etal-influenceofthehcvsubtypeonthevirologicalresponsetopegylatedinterferonandribavirintherapy-2009","role":"author","urls":{},"keyword":["Adult Antiviral Agents/ administration & dosage Drug Therapy","Chronic/drug therapy/virology Humans Interferon-alpha/ administration & dosage Male Middle Aged Recombinant Proteins Ribavirin/ administration & dosage Treatment Outcome","Combination Female Genetic Variation Genome","Viral Hepacivirus/drug effects/genetics Hepatitis C"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":["adult antiviral agents/ administration & dosage drug therapy","chronic/drug therapy/virology humans interferon-alpha/ administration & dosage male middle aged recombinant proteins ribavirin/ administration & dosage treatment outcome","combination female genetic variation genome","viral hepacivirus/drug effects/genetics hepatitis c"],"search_terms":["influence","hcv","subtype","virological","response","pegylated","interferon","ribavirin","therapy","legrand-abravanel","colson","leguillou-guillemette","alric","ravaux","lunel-fabiani","bouviers-alias","trimoulet","chaix","hezode","foucher","fontaine","roque-afonso","gassin","schvoerer","gaudy","roche","doffoel","d'alteroche","vallet","baazia","pozzetto","thibault","nousbaum","roulot","coppere","poynard","payan","izopet"],"title":"Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy","year":2009}